## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($326.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Don't Ignore The Insider Selling In Cencora**
- Source: Simply Wall Street | 20251221T120800 | Somewhat-Bearish | Relevance: 100%
- A Cencora (NYSE:COR) Senior VP recently sold US$1.4m worth of company stock at US$343 per share, representing a 19% decrease in their holding. While there were no insider purchases in the last year, Cencora exhibits strong insider ownership, profits, and growth. Investors should be aware of this selling activity, balanced against the company's positive financials and insider ownership stake, and consider the associated warning signs.

**2. Trust Point Inc. Invests $1.32 Million in Cencora, Inc. $COR**
- Source: MarketBeat | 20251221T123857 | Bullish | Relevance: 100%
- Trust Point Inc. has initiated a new position in Cencora, Inc. (NYSE:COR), acquiring 4,223 shares valued at approximately $1.32 million during the third quarter. This investment contributes to Cencora's significant institutional ownership, which stands at 97.52%. The company recently reported strong Q3 earnings, exceeding estimates with $3.84 EPS and $83.73 billion in revenue, and increased its quarterly dividend to $0.60.

**3. Voya Investment Management LLC Trims Position in Cencora, Inc. $COR**
- Source: MarketBeat | 20251220T134141 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC reduced its stake in Cencora, Inc. by 17.7% in Q3, selling 80,326 shares, bringing its total to 373,494 shares valued at $116.7 million. Despite this, institutional investors collectively own about 97.5% of the stock. Analyst sentiment remains largely positive, with an average target price of $373.25, and Cencora recently increased its quarterly dividend to $0.60 per share while beating EPS estimates.

**4. BDF Gestion Buys Shares of 12,508 Cencora, Inc. $COR**
- Source: MarketBeat | 20251220T095643 | Bullish | Relevance: 100%
- BDF Gestion recently purchased 12,508 shares of Cencora (NYSE:COR) valued at $3.909 million, establishing a new position. This comes as other large institutions also increased their stakes, and Wall Street analysts have upgraded their sentiment on the stock with higher price targets. Cencora also recently increased its quarterly dividend.

**5. Insider Sell Alert: Lazarus Krikorian Sells Shares of Cencora In**
- Source: GuruFocus | 20251220T002303 | Bearish | Relevance: 100%
- Lazarus Krikorian, Senior Vice President & Chief Accounting Officer at Cencora Inc (COR), sold 4,031 shares of the company on December 17, 2025, reducing his holdings to 17,154 shares. This transaction follows a pattern of insider selling at Cencora, with 28 insider sells and no buys over the past year. The stock is currently priced at $343.24, which is considered modestly overvalued compared to its GF Value of $275.38.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.0% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.81 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.0B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.81 |
| Forward P/E | 17.4 |
| Current P/E | 19.4 |
| YoY Growth | 11.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.5% to -1.5% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-1.24), momentum weakening. RSI neutral at 43. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.49% (CS: 24) | Neutral |
| RSI_14 | 43.1 | Neutral |
| MACD Histogram | -1.24 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 1.119x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $339.89
- **Stop Loss:** $326.27 (4.0% risk)
- **Target:** $353.51 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 88
- **Position Value:** $29,910.32
- **Portfolio %:** 29.91%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*